November 8, 2019
A first-in-class selective and potent IRAK4 degrader demonstrates robust in vitro and in vivo inhibition of TLR/IL-1R activation and inflammation
American College of Rheumatology Annual Meeting
Read More
October 26, 2019
Discovery of KYM-003, a potent and selective STAT3 degrader with anti-tumor activity in heme malignancies
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Liquid Tumors
Read More
June 18, 2019
IRAK4 degraders for MYD88 mutant lymphoma
International Conference on Malignant Lymphoma (ICML)
MYD88 Tumors
Read More
March 29, 2019
KYM-001, first-in-class oral IRAK4 protein degraders, induce tumor regression in a xenograft model of MYD-88 mutant ABC DLBCL alone and in combination with BTK inhibition
American Association for Cancer Research (AACR) Annual Meeting
MYD88 Tumors
Read More
January 28, 2019
Targeted Protein Degradation Mechanisms
Zhang, Y., Loh, C., Chen, J., & Mainolfi, N. (2019). Targeted protein degradation mechanisms. Drug Discovery Today: Technologies, 31, 53-60.
Read More
December 1, 2018
Targeted degradation of IRAK4 protein via heterobifunctional small molecules for treatment of MYD88 mutant lymphoma
American Society of Hematology (ASH) Annual Meeting
MYD88 Tumors
Read More
October 9, 2017
Targeted Protein Degradation (chapter 9), Annual reports in medicine chemistry
Mainolfi, N., & Rasmusson, T. (2017). Targeted protein degradation. In R. A. Goodnow (Ed.), Annual reports in medicinal chemistry (Vol. 50, pp. 301-334). Academic Press.
Read More